exemestane Search Results


93
MedChemExpress exemestane
A) Cell viability of MDA-MB-231 cells following 24 h treatment with concentration gradients of <t>Exemestane,</t> with and without 10 µM Olaparib, as determined by MTT assay. B) Clonogenic survival assay of MDA-MB-231 cells treated with single-agent Exemestane in combination with Olaparib (24 h treatment). C) Cell cycle distribution of MDA-MB-231 cells treated with Exemestane (EXE, 25 µM) and Olaparib (OLAP, 10 µM), 72 h treatment, as determined by PI staining and flow cytometry. Upper, representative histograms, lower, quantification of cell cycle phase. D) Annexin V-FITC assay of MDA-MB-231 cells treated as in (C). Upper, representative scatterplots showing the percentage of cells in each quadrant, lower, quantification of apoptotic cells (Q3-2 and Q3-4 quadrants) for each treatment condition. Data expressed as mean ± SD of at three independent experiments. *** P < 0.001 by ANOVA.
Exemestane, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/Exemestane/bio_rxiv__2024__07__31__605956-126-2-6
Average 93 stars, based on 1 article reviews
exemestane - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

88
Toronto Research Chemicals 17β hydroxy exemestane
A) Cell viability of MDA-MB-231 cells following 24 h treatment with concentration gradients of <t>Exemestane,</t> with and without 10 µM Olaparib, as determined by MTT assay. B) Clonogenic survival assay of MDA-MB-231 cells treated with single-agent Exemestane in combination with Olaparib (24 h treatment). C) Cell cycle distribution of MDA-MB-231 cells treated with Exemestane (EXE, 25 µM) and Olaparib (OLAP, 10 µM), 72 h treatment, as determined by PI staining and flow cytometry. Upper, representative histograms, lower, quantification of cell cycle phase. D) Annexin V-FITC assay of MDA-MB-231 cells treated as in (C). Upper, representative scatterplots showing the percentage of cells in each quadrant, lower, quantification of apoptotic cells (Q3-2 and Q3-4 quadrants) for each treatment condition. Data expressed as mean ± SD of at three independent experiments. *** P < 0.001 by ANOVA.
17β Hydroxy Exemestane, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/17+beta-Hydroxy+Exemestane/pmc07252770-49-9-13
Average 88 stars, based on 1 article reviews
17β hydroxy exemestane - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

92
Selleck Chemicals exemestane
Mean percentage of fish (A) in each tank (± standard error) that were either male, female, or sex changing, as determined by gonadal histology. In females, (B) the mean percentage of fish per tank (± standard error) with some proportion of cortical alveolus (CA) stage oocytes was determined, as well as (C) mean number of atretic follicles/cm2 ovary (± standard error). White and gray bars refer to control and <t>exemestane</t> treatments, respectively. Asterisks indicate either (*) p < 0.05 or (**) p < 0.0001.
Exemestane, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/Exemestane/pmc06311140-86-13-14
Average 92 stars, based on 1 article reviews
exemestane - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

90
Toronto Research Chemicals β hydroxyexemestane h942340
Mean percentage of fish (A) in each tank (± standard error) that were either male, female, or sex changing, as determined by gonadal histology. In females, (B) the mean percentage of fish per tank (± standard error) with some proportion of cortical alveolus (CA) stage oocytes was determined, as well as (C) mean number of atretic follicles/cm2 ovary (± standard error). White and gray bars refer to control and <t>exemestane</t> treatments, respectively. Asterisks indicate either (*) p < 0.05 or (**) p < 0.0001.
β Hydroxyexemestane H942340, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/17beta-Hydroxy+Exemestane/pmc09016448-55-5-9
Average 90 stars, based on 1 article reviews
β hydroxyexemestane h942340 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

88
LKT Laboratories exemestane
Mean percentage of fish (A) in each tank (± standard error) that were either male, female, or sex changing, as determined by gonadal histology. In females, (B) the mean percentage of fish per tank (± standard error) with some proportion of cortical alveolus (CA) stage oocytes was determined, as well as (C) mean number of atretic follicles/cm2 ovary (± standard error). White and gray bars refer to control and <t>exemestane</t> treatments, respectively. Asterisks indicate either (*) p < 0.05 or (**) p < 0.0001.
Exemestane, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/Exemestane/10__1158_slash_1078___0432__ccr___09___1013-102-65-66
Average 88 stars, based on 1 article reviews
exemestane - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

93
Biosynth Carbosynth exemestane exe
Effects of the combination of Genistein (G) with AIs <t>Exemestane</t> (Exe) ( A ), Anastrozole (Ana) ( B ), and Letrozole (Let) ( C ) on the viability of MCF-7aro cells. Cells stimulated with testosterone (T; 1 nM) were treated with G (1 or 10 µM) and Exe (1, 5 or 10 µM), Ana (1, 5 or 10 µM), or Let (1, 5 or 10 µM) for 3 days. Cells only treated with T were considered the control group (100% of cell viability). Data are presented as mean ± SEM of at least three independent experiments, performed in triplicate. Significant differences between control and treated cells are designated as * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001), and **** ( p < 0.0001), while differences between the AIs and the combination of G with AIs are indicated as # ( p < 0.05), ## ( p < 0.01) and ### ( p < 0.001).
Exemestane Exe, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/Exemestane/pmc10343543-81-0-2
Average 93 stars, based on 1 article reviews
exemestane exe - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Thermo Fisher exemestane
Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking <t>exemestane</t> were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.
Exemestane, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/Exemestane/pmc05684855-125-12-15
Average 90 stars, based on 1 article reviews
exemestane - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Toronto Research Chemicals 17β hydroxyexemestane 17 o β d glucuronide
Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking <t>exemestane</t> were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.
17β Hydroxyexemestane 17 O β D Glucuronide, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/17Beta-Hydroxy+Exemestane+17-O-Beta-D-Glucuronide/pmc04368747-69-3-10
Average 93 stars, based on 1 article reviews
17β hydroxyexemestane 17 o β d glucuronide - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology aromatase antibody
Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking <t>exemestane</t> were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.
Aromatase Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/Exemestane/pmc02782616-108-8-11
Average 90 stars, based on 1 article reviews
aromatase antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Toronto Research Chemicals hydroexemestane
Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking <t>exemestane</t> were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.
Hydroexemestane, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/17Beta-Hydroxy+Exemestane-d3/pm28404691-46-1-6
Average 86 stars, based on 1 article reviews
hydroexemestane - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
NSABP Foundation exemestane
Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking <t>exemestane</t> were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.
Exemestane, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exemestane/exemestane/10__2147_slash_ijwh__s69475-72-59-5
Average 90 stars, based on 1 article reviews
exemestane - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


A) Cell viability of MDA-MB-231 cells following 24 h treatment with concentration gradients of Exemestane, with and without 10 µM Olaparib, as determined by MTT assay. B) Clonogenic survival assay of MDA-MB-231 cells treated with single-agent Exemestane in combination with Olaparib (24 h treatment). C) Cell cycle distribution of MDA-MB-231 cells treated with Exemestane (EXE, 25 µM) and Olaparib (OLAP, 10 µM), 72 h treatment, as determined by PI staining and flow cytometry. Upper, representative histograms, lower, quantification of cell cycle phase. D) Annexin V-FITC assay of MDA-MB-231 cells treated as in (C). Upper, representative scatterplots showing the percentage of cells in each quadrant, lower, quantification of apoptotic cells (Q3-2 and Q3-4 quadrants) for each treatment condition. Data expressed as mean ± SD of at three independent experiments. *** P < 0.001 by ANOVA.

Journal: bioRxiv

Article Title: PARP inhibition enhances exemestane efficacy in triple-negative breast cancer

doi: 10.1101/2024.07.31.605956

Figure Lengend Snippet: A) Cell viability of MDA-MB-231 cells following 24 h treatment with concentration gradients of Exemestane, with and without 10 µM Olaparib, as determined by MTT assay. B) Clonogenic survival assay of MDA-MB-231 cells treated with single-agent Exemestane in combination with Olaparib (24 h treatment). C) Cell cycle distribution of MDA-MB-231 cells treated with Exemestane (EXE, 25 µM) and Olaparib (OLAP, 10 µM), 72 h treatment, as determined by PI staining and flow cytometry. Upper, representative histograms, lower, quantification of cell cycle phase. D) Annexin V-FITC assay of MDA-MB-231 cells treated as in (C). Upper, representative scatterplots showing the percentage of cells in each quadrant, lower, quantification of apoptotic cells (Q3-2 and Q3-4 quadrants) for each treatment condition. Data expressed as mean ± SD of at three independent experiments. *** P < 0.001 by ANOVA.

Article Snippet: Olaparib and Exemestane were purchased from MedChemExpress (MCE).

Techniques: Concentration Assay, MTT Assay, Clonogenic Cell Survival Assay, Staining, Flow Cytometry

A) Western blot analysis of DDR activation following Exemestane treatment (25, 50 and 100 µM) for 3 h. Left, western blot images, right, quantification of protein bands from western blot images by densitometry. β-actin levels were monitored as a loading control. Uncropped blot images are shown in Supplementary Fig. S5. Data expressed as mean ± SD of duplicate experiments. B) RPA1 foci (green) formation in MDA-MB-231 cells nuclei following treatment with Exemestane (50 µM, 24 h). Cisplatin (CIS, 50 µM, 24 h) was employed as positive control. Nuclear staining by DAPI (blue) also included. Scale bars = 10 µm. Left, representative images, right, quantification of cells with more than 10 RPA1 foci where a minimum of 200 nuclei were counted for each independent experiment. Data expressed as mean ± SD of two independent experiments. ** P < 0.01 and *** P < 0.001 by ANOVA.

Journal: bioRxiv

Article Title: PARP inhibition enhances exemestane efficacy in triple-negative breast cancer

doi: 10.1101/2024.07.31.605956

Figure Lengend Snippet: A) Western blot analysis of DDR activation following Exemestane treatment (25, 50 and 100 µM) for 3 h. Left, western blot images, right, quantification of protein bands from western blot images by densitometry. β-actin levels were monitored as a loading control. Uncropped blot images are shown in Supplementary Fig. S5. Data expressed as mean ± SD of duplicate experiments. B) RPA1 foci (green) formation in MDA-MB-231 cells nuclei following treatment with Exemestane (50 µM, 24 h). Cisplatin (CIS, 50 µM, 24 h) was employed as positive control. Nuclear staining by DAPI (blue) also included. Scale bars = 10 µm. Left, representative images, right, quantification of cells with more than 10 RPA1 foci where a minimum of 200 nuclei were counted for each independent experiment. Data expressed as mean ± SD of two independent experiments. ** P < 0.01 and *** P < 0.001 by ANOVA.

Article Snippet: Olaparib and Exemestane were purchased from MedChemExpress (MCE).

Techniques: Western Blot, Activation Assay, Control, Positive Control, Staining

A) Western blot analysis of DDR activation following treatment with Exemestane (25 µM) and Olaparib (10 µM) for 3 h. Left, western blot images, right, quantification of protein bands from western blot images by densitometry. β-actin levels were monitored as a loading control. NT = untreated control. Uncropped blot images are shown in Supplementary Fig. S6. Data expressed as mean ± SD of duplicate experiments. B) γH2AX levels in cells treated as in (A) for 24 h, as determined by γH2AX/PI double staining. Left, the percentage of γH2AX-positive cells (red gating) in each population where y-axis shows the level of γH2AX immunofluorescence and x-axis shows DNA content (PI). Data expressed as mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01 and *** P < 0.001 by ANOVA.

Journal: bioRxiv

Article Title: PARP inhibition enhances exemestane efficacy in triple-negative breast cancer

doi: 10.1101/2024.07.31.605956

Figure Lengend Snippet: A) Western blot analysis of DDR activation following treatment with Exemestane (25 µM) and Olaparib (10 µM) for 3 h. Left, western blot images, right, quantification of protein bands from western blot images by densitometry. β-actin levels were monitored as a loading control. NT = untreated control. Uncropped blot images are shown in Supplementary Fig. S6. Data expressed as mean ± SD of duplicate experiments. B) γH2AX levels in cells treated as in (A) for 24 h, as determined by γH2AX/PI double staining. Left, the percentage of γH2AX-positive cells (red gating) in each population where y-axis shows the level of γH2AX immunofluorescence and x-axis shows DNA content (PI). Data expressed as mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01 and *** P < 0.001 by ANOVA.

Article Snippet: Olaparib and Exemestane were purchased from MedChemExpress (MCE).

Techniques: Western Blot, Activation Assay, Control, Double Staining, Immunofluorescence

A) Schematic diagram indicating MDA-MB-231 cells were injected into nude mice and the mice were subsequently treated with Olaparib (50 mg/kg every two days for 30 days) and Exemestane (20 mg/kg every two days for 30 days) alone or in combination at the indicated times. B) Tumor volumes over 30 days of treatment with Olaparib and Exemestane alone or in combination (n = 5 per treatment group). C) Relative tumor weight of different treatment groups as indicated. D) Body weight of mice throughout the study. E) Representative images of H&E-staining of the tissue sections. Scale bars = 100 µm. F) Representative images of immunohistochemical staining for proliferation markers Ki67 (brown), vascular endothelial marker CD31 (brown) and DNA damage marker γH2AX, (brown) and TUNEL staining showing apoptotic cells (green). Nuclei staining (blue) also included. Left, representative images of xenografts used for evaluation, right, quantification of the percentage of positive area. Scale bars = 100 µm. Data are shown as the mean ± SD. * P < 0.05, ** P < 0.01 and *** P < 0.001 by ANOVA.

Journal: bioRxiv

Article Title: PARP inhibition enhances exemestane efficacy in triple-negative breast cancer

doi: 10.1101/2024.07.31.605956

Figure Lengend Snippet: A) Schematic diagram indicating MDA-MB-231 cells were injected into nude mice and the mice were subsequently treated with Olaparib (50 mg/kg every two days for 30 days) and Exemestane (20 mg/kg every two days for 30 days) alone or in combination at the indicated times. B) Tumor volumes over 30 days of treatment with Olaparib and Exemestane alone or in combination (n = 5 per treatment group). C) Relative tumor weight of different treatment groups as indicated. D) Body weight of mice throughout the study. E) Representative images of H&E-staining of the tissue sections. Scale bars = 100 µm. F) Representative images of immunohistochemical staining for proliferation markers Ki67 (brown), vascular endothelial marker CD31 (brown) and DNA damage marker γH2AX, (brown) and TUNEL staining showing apoptotic cells (green). Nuclei staining (blue) also included. Left, representative images of xenografts used for evaluation, right, quantification of the percentage of positive area. Scale bars = 100 µm. Data are shown as the mean ± SD. * P < 0.05, ** P < 0.01 and *** P < 0.001 by ANOVA.

Article Snippet: Olaparib and Exemestane were purchased from MedChemExpress (MCE).

Techniques: Injection, Staining, Immunohistochemical staining, Marker, TUNEL Assay

Mean percentage of fish (A) in each tank (± standard error) that were either male, female, or sex changing, as determined by gonadal histology. In females, (B) the mean percentage of fish per tank (± standard error) with some proportion of cortical alveolus (CA) stage oocytes was determined, as well as (C) mean number of atretic follicles/cm2 ovary (± standard error). White and gray bars refer to control and exemestane treatments, respectively. Asterisks indicate either (*) p < 0.05 or (**) p < 0.0001.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Mean percentage of fish (A) in each tank (± standard error) that were either male, female, or sex changing, as determined by gonadal histology. In females, (B) the mean percentage of fish per tank (± standard error) with some proportion of cortical alveolus (CA) stage oocytes was determined, as well as (C) mean number of atretic follicles/cm2 ovary (± standard error). White and gray bars refer to control and exemestane treatments, respectively. Asterisks indicate either (*) p < 0.05 or (**) p < 0.0001.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Control

Representative gonadal histology of control (A) female and (B) male fish, and exemestane-treated (C) female, (D) male, and (E) early sex changing black sea bass. Scale bar represents 100 µm. Arrowheads indicate atretic follicles. PO, primary growth oocyte; CA, cortical alveolus, or early secondary growth stage oocyte; SZ, spermatozoa; ST, spermatids; SC, spermatocytes; OV, ovarian tissue; T, testicular tissue.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Representative gonadal histology of control (A) female and (B) male fish, and exemestane-treated (C) female, (D) male, and (E) early sex changing black sea bass. Scale bar represents 100 µm. Arrowheads indicate atretic follicles. PO, primary growth oocyte; CA, cortical alveolus, or early secondary growth stage oocyte; SZ, spermatozoa; ST, spermatids; SC, spermatocytes; OV, ovarian tissue; T, testicular tissue.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Control

Representative gonadal histology of (A) cortical alveolus stage follicle in control females and (B) atresia in exemestane-fed females. Scale bar represents 20 µm. ZP, zona pellucida; NO, nucleolus; N, nucleus; CA, cortical alveolus; PO, primary growth oocyte; FC, follicle cells; AF, atretic follicle.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Representative gonadal histology of (A) cortical alveolus stage follicle in control females and (B) atresia in exemestane-fed females. Scale bar represents 20 µm. ZP, zona pellucida; NO, nucleolus; N, nucleus; CA, cortical alveolus; PO, primary growth oocyte; FC, follicle cells; AF, atretic follicle.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Control

Cluster analysis of 12 gonadal gene expression patterns in control male (CM), control female (CF), exemestane-treated male (EM), exemestane-treated female (EF), and exemestane-induced early sex changing fish (SC). Each row represents a single gene (labeled at right) and each column represents an individual (labeled at bottom). Colored blocks represent relative gene expression on a scale of high (yellow), medium (black), or low (blue), based on Pearson distance measurements. Brackets below surround either entirely testicular (male) or ovarian-dominated samples (F and SC), and bold numbers to the left indicate major gene clusters.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Cluster analysis of 12 gonadal gene expression patterns in control male (CM), control female (CF), exemestane-treated male (EM), exemestane-treated female (EF), and exemestane-induced early sex changing fish (SC). Each row represents a single gene (labeled at right) and each column represents an individual (labeled at bottom). Colored blocks represent relative gene expression on a scale of high (yellow), medium (black), or low (blue), based on Pearson distance measurements. Brackets below surround either entirely testicular (male) or ovarian-dominated samples (F and SC), and bold numbers to the left indicate major gene clusters.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Gene Expression, Control, Labeling

Relative mRNA expression (mean ± standard error, normalized to eef1a) of cluster 1 genes (esr1, parg, and pdcd4) in male (M), female, (F), and early sex changing (SC) fish. White and gray bars refer to control and exemestane treatments, respectively. Different letters denote significant differences.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Relative mRNA expression (mean ± standard error, normalized to eef1a) of cluster 1 genes (esr1, parg, and pdcd4) in male (M), female, (F), and early sex changing (SC) fish. White and gray bars refer to control and exemestane treatments, respectively. Different letters denote significant differences.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Expressing, Control

Relative mRNA expression (mean ± standard error, normalized to eef1a) of cluster 2 genes (amh, cyp19a1a, esr2b, cyp11b, and rif1) in male (M), female, (F), and early sex changing (SC) fish. White and gray bars refer to control and exemestane treatments, respectively. Different letters denote significant differences.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Relative mRNA expression (mean ± standard error, normalized to eef1a) of cluster 2 genes (amh, cyp19a1a, esr2b, cyp11b, and rif1) in male (M), female, (F), and early sex changing (SC) fish. White and gray bars refer to control and exemestane treatments, respectively. Different letters denote significant differences.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Expressing, Control

Relative mRNA expression (mean ± standard error, normalized to eef1a) of cluster 3 genes (zpc2, fabp11, aen, and casp9) in male (M), female, (F), and early sex changing (SC) fish. White and gray bars refer to control and exemestane treatments, respectively. Different letters denote significant differences.

Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology

Article Title: Initiation of sex change and gonadal gene expression in black sea bass ( Centropristis striata ) exposed to exemestane, an aromatase inhibitor

doi: 10.1016/j.cbpa.2018.10.024

Figure Lengend Snippet: Relative mRNA expression (mean ± standard error, normalized to eef1a) of cluster 3 genes (zpc2, fabp11, aen, and casp9) in male (M), female, (F), and early sex changing (SC) fish. White and gray bars refer to control and exemestane treatments, respectively. Different letters denote significant differences.

Article Snippet: Briefly, gelatin (Knox, Kraft Foods Global, Inc., Northfield, IL, USA; 0.008g/g diet) and exemestane (Selleck Chemicals, Houston, TX, USA, 1 mg/g diet) were dissolved in hot water (17 ml/g gelatin) and ethanol (0.067 ml/mg exemestane), respectively, combined, and mixed vigorously with Skretting Europa 6 mm feed.

Techniques: Expressing, Control

Effects of the combination of Genistein (G) with AIs Exemestane (Exe) ( A ), Anastrozole (Ana) ( B ), and Letrozole (Let) ( C ) on the viability of MCF-7aro cells. Cells stimulated with testosterone (T; 1 nM) were treated with G (1 or 10 µM) and Exe (1, 5 or 10 µM), Ana (1, 5 or 10 µM), or Let (1, 5 or 10 µM) for 3 days. Cells only treated with T were considered the control group (100% of cell viability). Data are presented as mean ± SEM of at least three independent experiments, performed in triplicate. Significant differences between control and treated cells are designated as * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001), and **** ( p < 0.0001), while differences between the AIs and the combination of G with AIs are indicated as # ( p < 0.05), ## ( p < 0.01) and ### ( p < 0.001).

Journal: Molecules

Article Title: In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment

doi: 10.3390/molecules28134893

Figure Lengend Snippet: Effects of the combination of Genistein (G) with AIs Exemestane (Exe) ( A ), Anastrozole (Ana) ( B ), and Letrozole (Let) ( C ) on the viability of MCF-7aro cells. Cells stimulated with testosterone (T; 1 nM) were treated with G (1 or 10 µM) and Exe (1, 5 or 10 µM), Ana (1, 5 or 10 µM), or Let (1, 5 or 10 µM) for 3 days. Cells only treated with T were considered the control group (100% of cell viability). Data are presented as mean ± SEM of at least three independent experiments, performed in triplicate. Significant differences between control and treated cells are designated as * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001), and **** ( p < 0.0001), while differences between the AIs and the combination of G with AIs are indicated as # ( p < 0.05), ## ( p < 0.01) and ### ( p < 0.001).

Article Snippet: Exemestane (Exe) (Carbosynth, Berkshire, UK), Genistein (G) from Glycine max , Anastrazole (Ana), Letrozole (Let), Casodex (CDX), ICI 182,780 and 4-[2-phenyl-5,7, bis (trifluoromethyl) pyrazole [1,5-a]pyrimidin-3-yl]phenol (PHTPP) (Sigma-Aldrich Co., Saint Louis, MO, USA) were prepared in 100% DMSO (Sigma-Aldrich Co., Saint Louis, MO, USA).

Techniques: Control

Effects on cell cycle of MCF-7aro of Genistein (G) alone or in combination with  Exemestane (Exe)  for 3 days.

Journal: Molecules

Article Title: In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment

doi: 10.3390/molecules28134893

Figure Lengend Snippet: Effects on cell cycle of MCF-7aro of Genistein (G) alone or in combination with Exemestane (Exe) for 3 days.

Article Snippet: Exemestane (Exe) (Carbosynth, Berkshire, UK), Genistein (G) from Glycine max , Anastrazole (Ana), Letrozole (Let), Casodex (CDX), ICI 182,780 and 4-[2-phenyl-5,7, bis (trifluoromethyl) pyrazole [1,5-a]pyrimidin-3-yl]phenol (PHTPP) (Sigma-Aldrich Co., Saint Louis, MO, USA) were prepared in 100% DMSO (Sigma-Aldrich Co., Saint Louis, MO, USA).

Techniques: Control

Effects of the combination of Genistein (G) with Exemestane (Exe) on the expression levels of cyclin E, cleaved PARP, and pro-caspase-7 in MCF-7aro cells. Cells were stimulated with Testosterone (T) (1 nM) and treated with G (1 or 10 µM) with or without Exe (10 µM) for 3 days. Cells treated only with T were considered the control group. Representative Western blot ( A ) and densitometric analysis ( B ) of cyclin E, cleaved PARP, and pro-caspase-7. β-Actin or total PARP was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control. The results are presented as mean ± SEM of at least three independent experiments. Significant differences between control and treated cells are designated as * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001) and **** ( p < 0.0001), while differences between Exe and its combination with G are indicated as # ( p < 0.05) and ## ( p < 0.01).

Journal: Molecules

Article Title: In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment

doi: 10.3390/molecules28134893

Figure Lengend Snippet: Effects of the combination of Genistein (G) with Exemestane (Exe) on the expression levels of cyclin E, cleaved PARP, and pro-caspase-7 in MCF-7aro cells. Cells were stimulated with Testosterone (T) (1 nM) and treated with G (1 or 10 µM) with or without Exe (10 µM) for 3 days. Cells treated only with T were considered the control group. Representative Western blot ( A ) and densitometric analysis ( B ) of cyclin E, cleaved PARP, and pro-caspase-7. β-Actin or total PARP was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control. The results are presented as mean ± SEM of at least three independent experiments. Significant differences between control and treated cells are designated as * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001) and **** ( p < 0.0001), while differences between Exe and its combination with G are indicated as # ( p < 0.05) and ## ( p < 0.01).

Article Snippet: Exemestane (Exe) (Carbosynth, Berkshire, UK), Genistein (G) from Glycine max , Anastrazole (Ana), Letrozole (Let), Casodex (CDX), ICI 182,780 and 4-[2-phenyl-5,7, bis (trifluoromethyl) pyrazole [1,5-a]pyrimidin-3-yl]phenol (PHTPP) (Sigma-Aldrich Co., Saint Louis, MO, USA) were prepared in 100% DMSO (Sigma-Aldrich Co., Saint Louis, MO, USA).

Techniques: Expressing, Control, Western Blot

Influence of aromatase on the effects induced by Genistein (G) alone and when combined with Exemestane (Exe) in MCF-7aro cells. ( A ) Effects of G (1–10 µM) on the viability of MCF-7aro cells stimulated with Testosterone (T) (1 nM) or estradiol (E 2 ) (1 nM), after 3 days. Cells treated only with T or E 2 were considered the control group. ( B ) Representative Western blot and densitometric analysis of the effects of G (1 and 10 µM) with or without Exe (10 µM) on the expression levels of aromatase, after 8 h exposure. Β-Actin was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control (T-treated cells). The results are presented as mean ± SEM of at least three independent experiments. Significant differences between control and treated cells are designated as ** ( p < 0.01) and *** ( p < 0.001) while differences between cells treated with G and stimulated with T versus E 2 are denoted as & ( p < 0.05) and &&&& ( p < 0.0001), and differences between Exe and its combination with G are indicated as ## ( p < 0.01). MIC: placenta microsomes (positive control).

Journal: Molecules

Article Title: In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment

doi: 10.3390/molecules28134893

Figure Lengend Snippet: Influence of aromatase on the effects induced by Genistein (G) alone and when combined with Exemestane (Exe) in MCF-7aro cells. ( A ) Effects of G (1–10 µM) on the viability of MCF-7aro cells stimulated with Testosterone (T) (1 nM) or estradiol (E 2 ) (1 nM), after 3 days. Cells treated only with T or E 2 were considered the control group. ( B ) Representative Western blot and densitometric analysis of the effects of G (1 and 10 µM) with or without Exe (10 µM) on the expression levels of aromatase, after 8 h exposure. Β-Actin was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control (T-treated cells). The results are presented as mean ± SEM of at least three independent experiments. Significant differences between control and treated cells are designated as ** ( p < 0.01) and *** ( p < 0.001) while differences between cells treated with G and stimulated with T versus E 2 are denoted as & ( p < 0.05) and &&&& ( p < 0.0001), and differences between Exe and its combination with G are indicated as ## ( p < 0.01). MIC: placenta microsomes (positive control).

Article Snippet: Exemestane (Exe) (Carbosynth, Berkshire, UK), Genistein (G) from Glycine max , Anastrazole (Ana), Letrozole (Let), Casodex (CDX), ICI 182,780 and 4-[2-phenyl-5,7, bis (trifluoromethyl) pyrazole [1,5-a]pyrimidin-3-yl]phenol (PHTPP) (Sigma-Aldrich Co., Saint Louis, MO, USA) were prepared in 100% DMSO (Sigma-Aldrich Co., Saint Louis, MO, USA).

Techniques: Control, Western Blot, Expressing, Positive Control

Influence of hormone receptors ERα, ERβ, and AR on the effects induced by Genistein (G) alone and when combined with Exemestane (Exe) in MCF-7aro cells. ( A ) Effects of G (1–10 µM) on the viability of MCF-7aro cells stimulated with Testosterone (T) (1 nM) and treated with or without ICI (100 nM) or PHTPP (1 µM) or CDX (1 µM), after 3 days. Cells treated only with T with or without ICI, PHTPP, or CDX were considered the control group. ( B ) Representative Western blot and densitometric analysis of the effects of G (1 and 10 µM) with or without Exe (10 µM) on the expression levels of ERα, ERβ, and AR, after 3 days. β-Actin was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control (T-treated cells). The results are presented as mean ± SEM of at least three inde-pendent experiments. Significant differences between control and treated cells are designated as ** ( p < 0.01), *** ( p < 0.001), and **** ( p < 0.0001), while differences between cells treated with G and incubated with T with or without ICI, PHTPP or CDX are denoted as & ( p < 0.05) and &&&& ( p < 0.0001).

Journal: Molecules

Article Title: In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment

doi: 10.3390/molecules28134893

Figure Lengend Snippet: Influence of hormone receptors ERα, ERβ, and AR on the effects induced by Genistein (G) alone and when combined with Exemestane (Exe) in MCF-7aro cells. ( A ) Effects of G (1–10 µM) on the viability of MCF-7aro cells stimulated with Testosterone (T) (1 nM) and treated with or without ICI (100 nM) or PHTPP (1 µM) or CDX (1 µM), after 3 days. Cells treated only with T with or without ICI, PHTPP, or CDX were considered the control group. ( B ) Representative Western blot and densitometric analysis of the effects of G (1 and 10 µM) with or without Exe (10 µM) on the expression levels of ERα, ERβ, and AR, after 3 days. β-Actin was used as a loading control. The protein expression obtained for treated cells was normalized in relation to the protein expression of the control (T-treated cells). The results are presented as mean ± SEM of at least three inde-pendent experiments. Significant differences between control and treated cells are designated as ** ( p < 0.01), *** ( p < 0.001), and **** ( p < 0.0001), while differences between cells treated with G and incubated with T with or without ICI, PHTPP or CDX are denoted as & ( p < 0.05) and &&&& ( p < 0.0001).

Article Snippet: Exemestane (Exe) (Carbosynth, Berkshire, UK), Genistein (G) from Glycine max , Anastrazole (Ana), Letrozole (Let), Casodex (CDX), ICI 182,780 and 4-[2-phenyl-5,7, bis (trifluoromethyl) pyrazole [1,5-a]pyrimidin-3-yl]phenol (PHTPP) (Sigma-Aldrich Co., Saint Louis, MO, USA) were prepared in 100% DMSO (Sigma-Aldrich Co., Saint Louis, MO, USA).

Techniques: Control, Western Blot, Expressing, Incubation

Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking exemestane were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.

Journal: Pharmacology Research & Perspectives

Article Title: Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy

doi: 10.1002/prp2.330

Figure Lengend Snippet: Comparison of estradiol levels in breast cancer patients on AI being treated with vaginal estradiol by ELISA versus estimation by LC ‐ MS / MS method: The serum samples were collected at various intervals from three patients who were on Estring ® to measure estradiol concentrations by two different ELISA kits, Invitrogen, and IBL . A few of these samples were also submitted for LC ‐ MS / MS analysis conducted by ARUP laboratories for the comparison purposes. The red line indicates limit of detection (LOD) for ELISA. 2A. Patient #1 was on letrozole and it was found that estradiol levels were varied between two different ELISA kits. 2B. The estrogen levels measured for patient #5 showed similar results by two ELISA kits at baseline, week 2 and week 4 (<3.0 pg/dl); whereas for week 8, the levels by Invitrogen kit was higher than IBL kit. Discrepancy was also found in week 2 results (8.6 pg/mL) by LC ‐ MS / MS analysis. 2C. The baseline estradiol results for patient #7 who was taking exemestane were highest at baseline determined by both IBL kit and LC ‐ MS / MS assay. 2D. Retesting of a few stored samples was done and consistency in the estradiol values was observed.

Article Snippet: This suggests that the IBL kit may have had more cross‐reactivity with exemestane than the Invitrogen kit.

Techniques: Comparison, Enzyme-linked Immunosorbent Assay, Liquid Chromatography with Mass Spectroscopy

Patient demographics with history of stage I–III estrogen receptor‐positive breast cancer taking adjuvant aromatase inhibitor therapy

Journal: Pharmacology Research & Perspectives

Article Title: Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy

doi: 10.1002/prp2.330

Figure Lengend Snippet: Patient demographics with history of stage I–III estrogen receptor‐positive breast cancer taking adjuvant aromatase inhibitor therapy

Article Snippet: This suggests that the IBL kit may have had more cross‐reactivity with exemestane than the Invitrogen kit.

Techniques: Adjuvant